SAN DIEGO--(BUSINESS WIRE)--Metabasis Therapeutics (Nasdaq: MBRX) announced today that an oral presentation summarizing the results from the Company’s Phase 2a clinical trial for MB07803 was given at the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy), in Barcelona, Spain. MB07803 is the Company’s second-generation fructose-1,6-bisphosphatase (FBPase) inhibitor discovered and developed internally for the treatment of type 2 diabetes. MB07803 was found to be safe and well tolerated in this study and met the primary efficacy endpoint of a significant reduction in fasting plasma glucose (FPG).
